Who Supplies Serum to India from MALI

To import finished pharmaceutical formulations containing serum into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the manufacturing site and the product be registered. The registration process involves obtaining a Registration Certificate for the manufacturing premises and an Import License for the specific drug. The application must be submitted to the Drugs Controller General of India (DCGI) at CDSCO. The required documents include a Free Sale Certificate, Good Manufacturing Practice (GMP) certificate, and a Certificate of Pharmaceutical Product (COPP). The registration certificate and import license are valid for three years from the date of issue.

Imported finished pharmaceutical formulations containing serum must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided. Port inspections by customs drug inspectors are conducted to ensure product quality and safety.

In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished formulations containing serum. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy emphasizes compliance with the Drugs and Cosmetics Act and associated rules.

India imports finished serum formulations to meet the demand for patented or branded products, specialized dosage forms, and formulations not produced domestically. The market size for serum formulations in India is substantial, with a total export market of $27.1 million across 341 exporters to 122 countries. This indicates a significant demand for serum formulations within the country.

The import duty for finished pharmaceutical formulations containing serum under HS Code 30029090 is 10% Basic Customs Duty (BCD). An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 10.30%. There are no additional duties or exemptions for imports from Mali.

India sources finished serum formulations from Mali due to the availability of patented formulations, specialized dosage forms, and high-quality products. Mali's share in India's serum formulation imports is modest, but it offers unique products not readily available from other suppliers. Other major suppliers include China, Germany, and the United States.

India imports finished serum formulations from Mali to access unique patented formulations, specialized dosage forms, and high-quality products not readily available from other suppliers. Mali's competitive advantage lies in its ability to produce formulations that meet specific therapeutic needs, thereby complementing India's domestic manufacturing capabilities.

Compared to other origins like China, the European Union, and the United States, Mali offers competitive pricing and unique product offerings. While other suppliers may provide a broader range of products, Mali's specialized formulations and quality standards present a unique advantage for Indian importers seeking specific serum formulations.

Potential risks for Indian importers sourcing serum formulations from Mali include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should establish contingency plans and maintain open communication with suppliers.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and product quality.
5. 5Regulatory Compliance: Stay updated on regulatory changes in both India and Mali to ensure continuous compliance.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration Certificate: Register the manufacturing premises with CDSCO.
3. 3CDSCO Import License: Apply for an import license for the specific drug.
4. 4No Objection Certificate (NOC): If applicable, obtain an NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30029090 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance with specifications.
2. 2Certificate of Pharmaceutical Product (COPP): Indicating product registration status in Mali.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating adherence to international manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed information on the drug substance.
5. 5Stability Data: Adhering to ICH Zone IV guidelines.
6. 6Free Sale Certificate: Indicating that the product is freely sold in Mali.
7. 7Manufacturer Authorization: Authorizing the supplier to export the product.

Upon arrival in India, imported serum formulations undergo inspection by CDSCO port inspectors. Mandatory batch testing is conducted, including sample collection and analysis. Timelines for testing vary, but importers should anticipate potential delays. If a batch fails quality testing, it may be rejected, leading to potential financial losses. Common quality issues from Mali include discrepancies in labeling and packaging.

Importers must renew CDSCO registrations and licenses annually. Periodic audits of manufacturing facilities in Mali are conducted to ensure ongoing compliance with international standards. Change control procedures must be documented, and pharmacovigilance systems should be in place for